TAL
APLS

TIG Advisors LLC’s Apellis Pharmaceuticals APLS Stock Holding History

TIG Advisors LLC’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-53,400
Closed -$3.2M – 53
2023
Q4 		$3.2M Buy
+53,400
New +$2.71M 0.4% 30

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TIG Advisors LLC's APLS Position: Q1 2026 in Review

TIG Advisors LLC opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 1,252,986 shares worth $50.4M. The stake represents 2.33% of the portfolio and ranks #12 among its holdings. This is a return to the name: TIG Advisors LLC previously reported a position in APLS as recently as Q4 2023.

TIG Advisors LLC first reported a position in APLS in Q4 2023 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • TIG Advisors LLC held 1,252,986 shares of Apellis Pharmaceuticals worth $50.4M as of Q1 2026.
  • Apellis Pharmaceuticals was a new TIG Advisors LLC position in Q1 2026.
  • Apellis Pharmaceuticals made up 2.33% of TIG Advisors LLC's portfolio in Q1 2026, its #12 holding.
  • TIG Advisors LLC first reported a position in Apellis Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on TIG Advisors LLC's 13F filing for Q1 2026, filed 15 May 2026.